These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 23560807)

  • 1. Current pharmacotherapeutical options for the prevention of kidney transplant rejection.
    Schaefer SM; Süsal C; Sommerer C; Zeier M; Morath C
    Expert Opin Pharmacother; 2013 Jun; 14(8):1029-41. PubMed ID: 23560807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.
    Helal I; Chan L
    Transplant Proc; 2011 Mar; 43(2):472-7. PubMed ID: 21440737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation.
    Armenti VT; Radomski JS; Moritz MJ; Gaughan WJ; Philips LZ; McGrory CH; Coscia LA;
    Clin Transpl; 2002; ():121-30. PubMed ID: 12971441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
    Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C
    Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus: preventing organ rejection in adult kidney transplant recipients.
    Dantal J
    Expert Opin Pharmacother; 2012 Apr; 13(5):767-78. PubMed ID: 22404500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcineurin inhibitor-free immunosuppression in kidney transplantation.
    Guerra G; Srinivas TR; Meier-Kriesche HU
    Transpl Int; 2007 Oct; 20(10):813-27. PubMed ID: 17645419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of acute rejection with antithymocyte globulin (Thymoglobuline): its potential to reduce corticosteroids.
    Cantarovich D
    J Nephrol; 2004; 17 Suppl 8():S40-6. PubMed ID: 15599885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in pharmacotherapy to treat kidney transplant rejection.
    Bamoulid J; Staeck O; Halleck F; Dürr M; Paliege A; Lachmann N; Brakemeier S; Liefeldt L; Budde K
    Expert Opin Pharmacother; 2015; 16(11):1627-48. PubMed ID: 26159444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance immunosuppression regimens: conversion, minimization, withdrawal, and avoidance.
    Yang H
    Am J Kidney Dis; 2006 Apr; 47(4 Suppl 2):S37-51. PubMed ID: 16567240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-2 receptor antibody reduces rejection rates and graft loss in live-donor kidney transplant recipients.
    Lim WH; Chang SH; Chadban SJ; Campbell SB; Dent H; Russ GR; McDonald SP
    Transplantation; 2009 Nov; 88(10):1208-13. PubMed ID: 19935375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
    Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
    Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppressive strategies to improve outcomes of kidney transplantation.
    Tang IY; Meier-Kriesche HU; Kaplan B
    Semin Nephrol; 2007 Jul; 27(4):377-92. PubMed ID: 17616271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A drug safety evaluation of everolimus in kidney transplantation.
    Holdaas H; Midtvedt K; Åsberg A
    Expert Opin Drug Saf; 2012 Nov; 11(6):1013-22. PubMed ID: 22954349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and evolving immunosuppressive regimens in kidney transplantation.
    Gaston RS
    Am J Kidney Dis; 2006 Apr; 47(4 Suppl 2):S3-21. PubMed ID: 16567239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alemtuzumab induction in deceased donor kidney transplantation.
    Shin M; Song SH; Kim JM; Kwon CH; Joh JW; Lee SK; Kim SJ
    Transplant Proc; 2011; 43(6):2365-78. PubMed ID: 21839271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effective immunosuppressive options for solid organ transplantation: a guide to lower cost for the renal transplant recipient in the USA.
    Farney AC; Doares W; Kaczmorski S; Rogers J; Stratta RJ
    Immunotherapy; 2010 Nov; 2(6):879-88. PubMed ID: 21091118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
    Nashan B
    Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excellent outcomes of ABO-incompatible kidney transplantation: a single-center experience.
    Uchida J; Kuwabara N; Machida Y; Iwai T; Naganuma T; Kumada N; Nakatani T
    Transplant Proc; 2012 Jan; 44(1):204-9. PubMed ID: 22310615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High immunologic risk living donor kidney transplant using bortezomib in a novel induction regimen without acute antibody mediated rejection.
    Dunn TB; Borja-Cacho D; Chinnakotla S; Finger E; Tamayo G; Verghese P; Kim Y; Manivel C; Kandaswamy R; Matas A; Pruett T; Noreen H; Krefting P; Maurer D
    Clin Transpl; 2011; ():381-7. PubMed ID: 22755435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based immunosuppression.
    Kandaswamy R; Humar A; Casingal V; Gillingham KJ; Ibrahim H; Matas AJ
    Transplantation; 2007 Mar; 83(6):722-6. PubMed ID: 17414704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.